BR112023021761A2 - Regime de dosagem de anti-ifnar1 para injeção subcutânea - Google Patents

Regime de dosagem de anti-ifnar1 para injeção subcutânea

Info

Publication number
BR112023021761A2
BR112023021761A2 BR112023021761A BR112023021761A BR112023021761A2 BR 112023021761 A2 BR112023021761 A2 BR 112023021761A2 BR 112023021761 A BR112023021761 A BR 112023021761A BR 112023021761 A BR112023021761 A BR 112023021761A BR 112023021761 A2 BR112023021761 A2 BR 112023021761A2
Authority
BR
Brazil
Prior art keywords
ifnar1
subcutaneous injection
dosing regime
relates
type
Prior art date
Application number
BR112023021761A
Other languages
English (en)
Portuguese (pt)
Inventor
Catharina Lindholm
Joachim Almquist
Lorin Roskos
Rajendra Tummala
Tomas Rouse
Lin Chia Yen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112023021761(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023021761A2 publication Critical patent/BR112023021761A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Devices For Medical Bathing And Washing (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR112023021761A 2021-04-23 2022-04-21 Regime de dosagem de anti-ifnar1 para injeção subcutânea BR112023021761A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (1)

Publication Number Publication Date
BR112023021761A2 true BR112023021761A2 (pt) 2023-12-26

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021761A BR112023021761A2 (pt) 2021-04-23 2022-04-21 Regime de dosagem de anti-ifnar1 para injeção subcutânea

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4306541A3 (enExample)
JP (2) JP7484027B2 (enExample)
KR (2) KR20250092298A (enExample)
CN (2) CN120392997A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (1) IL307748A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
US20250002590A1 (en) * 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2008093166A2 (en) 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
CN101909444B (zh) 2007-11-05 2013-09-18 米迪缪尼有限公司 硬皮病治疗方法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
ES2613055T3 (es) 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US11059897B2 (en) * 2018-09-18 2021-07-13 I-Mab Biopharma Us Limited Anti-IFNAR1 antibodies for treating autoimmune diseases
KR20210131354A (ko) * 2019-02-15 2021-11-02 아스트라제네카 아베 I형 인터페론-매개 장애
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
AU2021279277A1 (en) 2020-05-29 2023-02-02 Astrazeneca Ab Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20240327529A1 (en) 2020-11-18 2024-10-03 Astrazeneca Ab Steroid sparing
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
US20250002590A1 (en) 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
US20240360231A1 (en) 2024-10-31
CN120514844A (zh) 2025-08-22
CL2023003114A1 (es) 2024-04-19
US20220340669A1 (en) 2022-10-27
WO2022223714A1 (en) 2022-10-27
JP2024511227A (ja) 2024-03-12
US20230365698A1 (en) 2023-11-16
EP4306541A2 (en) 2024-01-17
MX2023012465A (es) 2024-04-04
CO2023015498A2 (es) 2023-11-30
SMT202300382T1 (it) 2024-01-10
JP7484027B2 (ja) 2024-05-15
PT4114465T (pt) 2023-11-03
DK4114465T5 (da) 2024-07-22
HUE063562T2 (hu) 2024-01-28
AU2022260531B2 (en) 2024-03-07
AU2022260531A1 (en) 2023-11-30
PL4114465T3 (pl) 2024-04-08
AU2022260531A9 (en) 2023-12-07
KR20230166134A (ko) 2023-12-06
JP2024102205A (ja) 2024-07-30
AU2024201743A1 (en) 2024-04-04
CN120392997A (zh) 2025-08-01
IL307748A (en) 2023-12-01
EP4114465A1 (en) 2023-01-11
TW202317182A (zh) 2023-05-01
HRP20231255T1 (hr) 2024-02-02
RS64821B1 (sr) 2023-12-29
US12060429B2 (en) 2024-08-13
LT4114465T (lt) 2023-11-10
ES2963757T3 (es) 2024-04-01
CA3216387A1 (en) 2022-10-27
FI4114465T3 (fi) 2023-10-31
SI4114465T1 (sl) 2023-11-30
KR20250092298A (ko) 2025-06-23
EP4306541A3 (en) 2024-03-27
DK4114465T3 (da) 2023-10-30
EP4114465B1 (en) 2023-08-30
US20240400699A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
BR112023021761A2 (pt) Regime de dosagem de anti-ifnar1 para injeção subcutânea
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112016018685A2 (pt) regime de dosagem com composto de fgf-18
MX2020004716A (es) Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
ZA202400851B (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2024009188A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
CO2021000229A2 (es) Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
UY38473A (es) Formulaciones farmacéuticas para una administración subcutánea
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
BR112023020732A2 (pt) Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b
AR125411A1 (es) Dosis